Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Axl RNAi
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral, Intraperitoneal, Parenteral, Topical, Oral, Subcutaneous, Intra-arterial, Intranasal, Intramuscular
01
Overview
Axl RNAi refers to RNA interference (RNAi) strategies, including small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs), designed to selectively silence the expression of the AXL receptor tyrosine kinase. AXL is a member of the TAM (Tyro3, AXL, Mer) receptor tyrosine kinase family and is activated by its ligand, growth arrest-specific 6 (Gas6). Overexpression and activation of AXL are implicated in tumor cell proliferation, survival, migration, invasion, metastasis, and the development of resistance to chemotherapeutic and targeted therapies across various cancers, including breast, lung, ovarian, and colorectal cancers. By targeting AXL mRNA for degradation, Axl RNAi inhibits downstream signaling pathways such as PI3K/Akt and MAPK/ERK, thereby reversing epithelial-to-mesenchymal transition (EMT) and suppressing malignant phenotypes in preclinical research.
- Other names
- Axl RNA interferenceAxl shRNAAxl siRNA
02
Targets
AXL (AXL receptor tyrosine kinase)
Beyond the preview
Go deeper on Axl RNAi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Axl RNAi.